The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1 trial: A phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
 
Li-Tzong Chen
Honoraria - PharmaEngine
Consulting or Advisory Role - PharmaEngine
Other Relationship - Merrimack
 
Jens T Siveke
Consulting or Advisory Role - Merrimack
 
Andrea Wang-Gillam
Consulting or Advisory Role - Merrimack; pfizer
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); EMD Serono (Inst); Halozyme (Inst); Merrimack (Inst); Newlink Genetics (Inst); OncoMed (Inst); pfizer (Inst); Precision Therapeutics (Inst); Prometheus (Inst)
 
Richard Hubner
No Relationships to Disclose
 
Shubham Pant
Consulting or Advisory Role - Celgene; Halozyme
 
Tomislav Dragovich
Employment - Taiho Pharmaceutical (I)
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Merrimack (Inst)
 
Vincent M. Chung
Consulting or Advisory Role - Celgene; Perthera
Speakers' Bureau - Celgene
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene
 
David Z. Chang
No Relationships to Disclose
 
Paul J. Ross
Honoraria - Celgene; Roche/Genentech; Sanofi; Sirtex Medical
Consulting or Advisory Role - Baxter; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Merck Serono; Roche/Genentech; Sirtex Medical
Research Funding - Sanofi
Travel, Accommodations, Expenses - Amgen; Bayer; Celgene; Merck Serono; Sanofi
 
Prasad Cooray
No Relationships to Disclose
 
Niall C. Tebbutt
No Relationships to Disclose
 
Fabio A. Franke
No Relationships to Disclose
 
Bruce Belanger
Employment - Merrimack
 
Navreet Dhindsa
Employment - Merrimack
Patents, Royalties, Other Intellectual Property - Merrimack
 
Floris De Jong
Employment - Baxalta; Merck Serono; Pharmacyclics
Stock and Other Ownership Interests - Amgen; Baxalta; Pharmacyclics
 
Khalid Mamlouk
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
Travel, Accommodations, Expenses - Merrimack
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Caris Life Sciences; Cell Therapeutics; CerRx; EmergingMed; HTG, Inc.; Insys Therapeutics; McKesson; Medelis; Medical Prognosis Institute; Medtronic; SynDevRx; Targeted Genetics
Honoraria - Celgene; Cerulean Pharma; Clarion Healthcare; Daiichi Sankyo; Genentech; Immunomedics; International Genomics Consortium; McKesson; Novartis; OncoMed; Peregrine Pharmaceuticals; Precision Medicine Research Associates, LLC; Puma Biotechnology
Consulting or Advisory Role - 3-V Biosciences; AgencyRx; Agenus; Aileron Therapeutics; Alethia Biotherapeutics; Alpha Cancer Technologies; Arsia Therapeutics; Arvinas; Azaya Therapeutics; Bellicum Pharmaceuticals; Biological Dynamics; Biomarin; Bionomics; Bristol-Myers Squibb; Buhl Oncology; CanBas; Caris Life Sciences; Cavion; Cerulean Pharma; CTI; CytRx Corporation; Daiichi Sankyo; dalian wanchun biotechnology; DNAtrix; Esperance Pharmaceuticals; Five Prime Therapeutics; Formula Pharmaceuticals; Halozyme; HealthCare Pharmaceuticals; Horizon Discovery; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Immunomedics; Inform Genomics; Innate Pharma; Insys Therapeutics; Invivodata; Kinex; Lilly; Lixte Biotechnology; Lorus; MBC Pharma; Medelis; MediaPharma; Medical Prognosis Institute; Merus; miRNA Therapeutics; Momenta Pharmaceuticals; Nereus Pharmaceuticals; Novartis; Nucana; Oncology Venture; Oncolytics; Oncolyze; OncoMed; Pain Therapeutics; Peregrine Pharmaceuticals; Pharmacyclics; Pharmatech; Pledpharma; Precision Medicine Research Associates, LLC; Puma Biotechnology; RadioRx; Reflexion Medical; RenovoRx; Samsung; Samumed; Senhwa Biosciences; Superlab Far East; SynDevRx; TD2; Teva; Theravance; TNI Biotech; Tolero Pharmaceuticals; Toray Industries; Trovagene; Vaccinex; VidaCare
Research Funding - 3-V Biosciences (Inst); Abraxis BioScience (Inst); Agios (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Plexxikon (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
Travel, Accommodations, Expenses - Aileron Therapeutics; Bionomics; Caris Life Sciences; Celgene; Cell Therapeutics; Cerulean Pharma; Cylene; Daiichi Sankyo; DNAtrix; Five Prime Therapeutics; FORMA Therapeutics; Halozyme; Innate Pharma; Lilly; McKesson; Medical Prognosis Institute; miRNA Therapeutics; Novartis; Oncolytics; Partners Healthcare; Quintiles; RadioRx; Senhwa Biosciences; Vaccinex